» Articles » PMID: 19903265

Altered Profiles of Intestinal Microbiota and Organic Acids May Be the Origin of Symptoms in Irritable Bowel Syndrome

Overview
Date 2009 Nov 12
PMID 19903265
Citations 222
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The profile of intestinal organic acids in irritable bowel syndrome (IBS) and its correlation with gastrointestinal (GI) symptoms are not clear. We hypothesized in this study that altered GI microbiota contribute to IBS symptoms through increased levels of organic acids.

Methods: Subjects were 26 IBS patients and 26 age- and sex-matched controls. Fecal samples were collected for microbiota analysis using quantitative real-time polymerase chain reaction and culture methods, and the determination of organic acid levels using high-performance liquid chromatography. Abdominal gas was quantified by image analyses of abdominal X-ray films. Subjects completed a questionnaire for GI symptoms, quality of life (QOL) and negative emotion.

Key Results: Irritable bowel syndrome patients showed significantly higher counts of Veillonella (P = 0.046) and Lactobacillus (P = 0.031) than controls. They also expressed significantly higher levels of acetic acid (P = 0.049), propionic acid (P = 0.025) and total organic acids (P = 0.014) than controls. The quantity of bowel gas was not significantly different between controls and IBS patients. Finally, IBS patients with high acetic acid or propionic acid levels presented with significantly worse GI symptoms, QOL and negative emotions than those with low acetic acid or propionic acid levels or controls.

Conclusions & Inferences: These results support the hypothesis that both fecal microbiota and organic acids are altered in IBS patients. A combination of Veillonella and Lactobacillus is known to produce acetic and propionic acid. High levels of acetic and propionic acid may associate with abdominal symptoms, impaired QOL and negative emotions in IBS.

Citing Articles

The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial.

Schropp N, Bauer A, Stanislas V, Huang K, Lesker T, Bielecka A Microbiome. 2025; 13(1):52.

PMID: 39940045 PMC: 11817299. DOI: 10.1186/s40168-024-02016-3.


The Efficacy of the Low-FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) Diet in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.

Khan Z, Muhammad S, Amin M, Gul A Cureus. 2025; 17(1):e77053.

PMID: 39917138 PMC: 11799870. DOI: 10.7759/cureus.77053.


The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis.

Yoshida N, Yasuda T, Inagaki Y, Hasegawa D, Fukumoto K, Murakami T J Anus Rectum Colon. 2025; 9(1):105-116.

PMID: 39882236 PMC: 11772784. DOI: 10.23922/jarc.2024-068.


Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.

Garcia Mansilla M, Rodriguez Sojo M, Lista A, Ayala Mosqueda C, Ruiz Malagon A, Galvez J Nutrients. 2025; 17(1.

PMID: 39796588 PMC: 11723002. DOI: 10.3390/nu17010155.


Meta-analysis of gut microbiota alterations in patients with irritable bowel syndrome.

Li X, Li X, Xiao H, Xu J, He J, Xiao C Front Microbiol. 2025; 15():1492349.

PMID: 39777150 PMC: 11703917. DOI: 10.3389/fmicb.2024.1492349.